The Bert M. Glaser, MD Award for Innovative Research in Retina
This award is given to an early-career investigator in recognition of the discovery of a drug or technique, or the understanding of a mechanism of disease, that is novel and has profoundly changed our understanding and/or treatment of a retinal disease or condition. The discovery must have taken place within five years of the date of application.
This award honors the life of Bert M. Glaser, MD, a retinal surgeon, researcher, innovator and teacher for over 30 years. The award was established by his family to honor his legacy as an innovator and as a retina specialist.
The $10,000 award is supported by the Glaser family through the ARVO Foundation. The first award was issued in 2019.
- Must be a basic scientist or clinician-scientist in retina
- Must be within five years of completion of a post-doctoral fellowship or clinical fellowship
- Must be an ARVO member
- May be a resident or citizen of any country
- May be affiliated with a university, hospital, private practice or company
Letters of Support
Two letters are required to support this nomination: one from the Nominator and one from a secondary Supporter.
The Nominator is responsible for obtaining and uploading his/her own letter of nomination and the letter of the secondary Supporter. Nominators and Supporters may only support one nomination; the Nominator and the Supporter may not be from the same institution. Foundation and ARVO Officers, Board members and Awards Committee members are not eligible to nominate or be nominated for an award during their terms, or to offer seconding letters of support.
The letters should address the following:
- How the nominee has contributed to the discovery of a drug or technique, or the understanding of a mechanism of disease, that is novel and has profoundly changed our understanding and/or treatment of a retinal disease or condition
- The timeframe in which the discovery or understanding was achieved (must be by 9/1/2016 or later)
- Mention of any publications that reference this discovery or understanding
The award will be disbursed to the winner’s employer for the sole purpose of furthering the winner’s research. The applicant’s employer must be willing to receive and disburse the award monies under the guidelines of ARVO. It is the responsibility of the applicant to ensure his/her employer can and will accept the award monies for the sole purpose set out in this award, as specified in the criteria, including that the employer agrees not to apply or withhold administrative fees or indirect costs.
Applications open on July 1
Applications close on Sept. 1
Recipient notified in December
2022 recipient: Magdalena Renner, PhD
Magdalena Renner, PhD, is leading the Human Organoid Platform at the Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland. Together with her team she is optimizing the culture of retinal organoids as a model for the human retina and retinal disease. She is particularly interested in enabling the mass production of retinal organoids and other cell types of the human eye to facilitate high-content compound screening and testing of novel gene therapy tools.